Greenwich LifeSciences, Inc. (GLSI) Fair Value 2026

GLSI · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 6 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-15, Greenwich LifeSciences, Inc. (GLSI) trades at $19.54, approximately 258% above CirclFi’s Bayesian DCF fair value of $5.45. QOC: 4.3/10. 6/13 models active.

Key Facts

Ticker
GLSI
Price
$19.54
Quality Score
4.3/10
Value Trap Risk
—/100
Models Active
6/13
Last Updated
Strength: First Chicago suggests +101.5% upside with 12% confidence
Risk: Below-average Quality Score of 4.3/10 signals weak fundamentals

Is Greenwich LifeSciences, Inc. (GLSI) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, Greenwich LifeSciences, Inc. (GLSI) appears fairly valued as of : the median of 6 independent fair value estimates is $17.99, within 7.9% of the current price of $19.54. Estimates range from $1.06 to $39.38. GLSI scores 4.3/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Greenwich LifeSciences, Inc. Stock in 2026? →

Valuation Matrix

6 Intrinsic Value Models vs. Current Price ($19.54)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$5.45 -72.1%
CUCE Ensemble
Low Conviction
$13.41 -31.4%
First Chicago
Low Conviction
$39.38 +101.5%

Unlock the Full Matrix

Access 3 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is Greenwich LifeSciences, Inc. (GLSI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Greenwich LifeSciences, Inc.'s intrinsic value is estimated at a composite $18.57, showing conflicting signals at the current price of $19.54. While the average implied return is -5.0%, model disagreement is elevated with a gap of +196.1% between the most bullish and bearish estimates. The most optimistic model, First Chicago, places fair value at $39.38 (+101.5%), while Dynamic NAV — the most conservative — estimates $1.06 (-94.6%). This +196.1% gap reflects genuine analytical uncertainty about Greenwich LifeSciences, Inc.'s intrinsic worth.

What Do the Models Say About GLSI?

6 of 13 models are currently active for GLSI. Of these, 3 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates GLSI's intrinsic value at $5.45, implying -72.1% downside from the current price. See which stocks rank higher →

How Does GLSI Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, GLSI ranks #300 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Greenwich LifeSciences, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating GLSI should weigh these sector-specific dynamics alongside our model-derived fair values.

Is GLSI a Value Trap?

The Value Trap algorithm is not active for GLSI. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for Greenwich LifeSciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Greenwich LifeSciences, Inc.'s fundamental quality profile registers 4.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +196.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GLSI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GLSI's 6 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Greenwich LifeSciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Greenwich LifeSciences, Inc.

What is Greenwich LifeSciences, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Greenwich LifeSciences, Inc. (GLSI) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $5.45. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GLSI overvalued or undervalued right now?

At $19.54, 3 of 6 active models suggest GLSI may be undervalued, while 3 indicate potential overvaluation. The median of all 6 fair value estimates is $17.99, within 7.9% of the current price of $19.54 — a consensus view that GLSI is fairly valued. The assessment depends on which methodology best fits Greenwich LifeSciences, Inc.'s business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.3 mean for GLSI?

Greenwich LifeSciences, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on GLSI?

CirclFi analyzes GLSI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Is GLSI a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for GLSI at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 6-model valuation engine, Greenwich LifeSciences, Inc. (GLSI) has a median fair value of $17.99 — within 7.9% of the current price of $19.54 — as of 2026-07-15.” Source: circlfi.com/stock/GLSI/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on GLSI.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access